Assessment of NORE1A as a putative tumor suppressor in human neuroblastoma

The putative tumor suppressor NORE1A (RASSF5) is a member of the Ras association domain family and is commonly inactivated in human cancer. The closely related gene family member and functional collaborator RASSF1A is a bona fide tumor suppressor and is frequently involved in neuroblastoma. In the present study, we sought to investigate the role of NORE1A in human neuroblastoma. A panel of tumors (36 neuroblastomas and 4 ganglioneuromas) and neuroblastoma cell lines was assessed for NORE1A gene expression by Taqman quantitative RT‐PCR. Promoter methylation was quantitatively determined by methylation sensitive pyrosequencing. The antitumourigenic role was functionally investigated in Nore1a transfected SK‐N‐BE (2) cells by fluorescent inhibition of caspase activity and BrdU incorporation assays. Neuroblastoma cells showed very low or absent NORE1A mRNA expression, which could not be reversed by trichostatin A or 5‐aza‐cytidine treatments. Neuroblastoma tumors showed suppressed NORE1A gene expression that was particularly pronounced in cases without MYCN amplification or 1p loss. Methylation of the NORE1A promoter was not observed in primary tumors and only one out of seven neuroblastoma cell lines displayed weak partial methylation. Transient expression of Nore1a resulted in enhanced apoptosis and delayed cell cycle progression. In conclusion NORE1A appears to be strongly suppressed in neuroblastic tumors and reconstitution of its expression diminishes the tumorigenic phenotype. Promotor methylation is not a common mechanism responsible for NORE1A transcriptional suppression in this tumor type. © 2008 Wiley‐Liss, Inc.

[1]  O. Larsson,et al.  The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. , 2007, Endocrine-related cancer.

[2]  F. Speleman,et al.  Genome wide measurement of DNA copy number changes in neuroblastoma: dissecting amplicons and mapping losses, gains and breakpoints , 2006, Cytogenetic and Genome Research.

[3]  M. Nistal,et al.  Frequent promoter hypermethylation of RASSF1A and CASP8 in neuroblastoma , 2006, BMC Cancer.

[4]  W. Foulkes,et al.  Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis , 2006, Gut.

[5]  J. Minna,et al.  The Growth and Tumor Suppressor NORE1A Is a Cytoskeletal Protein That Suppresses Growth by Inhibition of the ERK Pathway* , 2006, Journal of Biological Chemistry.

[6]  C. Larsson,et al.  The Ras effector NORE1A is suppressed in follicular thyroid carcinomas with a PAX8-PPARgamma fusion. , 2006, The Journal of clinical endocrinology and metabolism.

[7]  G. Tonini,et al.  Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors , 2005, Oncogene.

[8]  F. Latif,et al.  Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. , 2005, Cancer research.

[9]  G. Pfeifer,et al.  The tumor suppressor RASSF1A in human carcinogenesis: an update. , 2005, Histology and histopathology.

[10]  Qiwei Yang,et al.  Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma , 2004, Clinical Cancer Research.

[11]  M. Fraga,et al.  CpG island promoter hypermethylation of the Ras-effector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer , 2004, Oncogene.

[12]  J. Avruch,et al.  Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases , 2004, Oncogene.

[13]  P. Tam,et al.  Ubiquitous Aberrant RASSF1A Promoter Methylation in Childhood Neoplasia1 , 2004, Clinical Cancer Research.

[14]  C. Larsson,et al.  The t(1;3) breakpoint-spanning genes LSAMP and NORE1 are involved in clear cell renal cell carcinomas. , 2003, Cancer cell.

[15]  G. Clark,et al.  The Pro-apoptotic Ras Effector Nore1 May Serve as a Ras-regulated Tumor Suppressor in the Lung* , 2003, Journal of Biological Chemistry.

[16]  G. Brodeur.  Neuroblastoma: biological insights into a clinical enigma , 2003, Nature Reviews Cancer.

[17]  J. Minna,et al.  NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers , 2003, Oncogene.

[18]  Kenichi Harada,et al.  Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines , 2002, Oncogene.

[19]  J. Avruch,et al.  RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1 , 2002, Oncogene.

[20]  R. Buchsbaum,et al.  Cell Signaling: Life or Death Decisions of Ras Proteins , 2002, Current Biology.

[21]  J. Avruch,et al.  The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1 , 2002, Oncogene.

[22]  R. Xavier,et al.  Identification of a Novel Ras-Regulated Proapoptotic Pathway , 2002, Current Biology.

[23]  C. Eng,et al.  RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours , 2001, Oncogene.

[24]  F. Speleman,et al.  Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there? , 2001, Medical and pediatric oncology.

[25]  A. Balmain,et al.  Integration of positive and negative growth signals during ras pathway activation in vivo. , 2000, Current opinion in genetics & development.

[26]  L. Skoog,et al.  The use of fine‐needle aspiration cytology in the molecular characterization of neuroblastoma in children , 1999, Cancer.

[27]  F. Hedborg,et al.  Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms. , 1995, Cancer research.

[28]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.